Merck, chasing Pfizer, claims study success for new pneumonia vaccine
Bio Pharma Dive
JULY 27, 2023
The pharma said its latest shot, which covers 21 strains of bacteria, cleared two Phase 3 trials and in some cases spurred a stronger immune response than Pfizer’s Prevnar 20.
Let's personalize your content